Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2018 October;66(5) > Minerva Cardioangiologica 2018 October;66(5):543-6

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Minerva Cardioangiologica 2018 October;66(5):543-6

DOI: 10.23736/S0026-4725.18.04638-8

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Efficacy of Pycnogenol® supplementation in remission phases of Sjögren syndrome

Roberta LUZZI 1, 2, Gianni BELCARO 1, 2 , Shu HU 1, 2, Beatrice FERAGALLI 1, 2, Morio HOSOI 1, 2, Mark DUGALL 1, 2, Andrea LEDDA 1, 2

1 IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy; 2 International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy


PDF


BACKGROUND: The aim of this study was to evaluate the effects of Pycnogenol® supplementation in otherwise healthy subjects with Sjögren syndrome (SS) in a remission phase, who experienced persisting symptoms impairing their quality of life.
METHODS: The control group receiving only standard treatment was composed of 14 subjects, the supplement group included 16 subjects who used Pycnogenol® supplementation.
RESULTS: ESR and oxidative stress levels were high in all subjects at inclusion; both decreased significantly with supplementation (P<0.05). Pycnogenol® significantly improved the majority of symptoms (dry eyes and mouth dryness), diminishing the need for corticosteroids and other treatments.
CONCLUSIONS: Pycnogenol® supplementation in patients with SS in a remission phase may be effective to control inflammation and reduce symptoms.


KEY WORDS: Sjogren’s syndrome - Pycnogenol® - Dietary supplements, inflammation

inizio pagina